Mainz Biomed (NASDAQ: MYNZ) is making significant strides in the fight against colorectal cancer with its innovative screening technology. The German biotech company, with U.S. offices in Berkeley, California, has developed a molecular diagnostic solution that could revolutionize how colorectal cancer is detected and potentially save countless lives.
Colorectal cancer remains a formidable threat, ranking as the second leading cause of cancer death in the United States. With over 100,000 cases diagnosed so far in 2024, the need for more effective screening methods is crucial. Mainz Biomed’s approach leverages cutting-edge mRNA technology to address this pressing health concern.
The company recently submitted an application to the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for its non-invasive colorectal cancer product. This designation, if granted, could accelerate the development and review process for this potentially life-saving technology.
What sets Mainz Biomed’s test apart is its remarkable sensitivity in detecting precancerous polyps. According to the company’s CFO, Bill Caragol, their mRNA-powered test has demonstrated a sensitivity for detecting advanced adenomas that is double that of products currently on the market. In clinical studies conducted between 2023 and 2024, Mainz’s test consistently showed accuracy above 80%, a significant improvement over existing stool-based tests that typically demonstrate efficacy in the 40% range for detecting advanced adenomas.
The company’s flagship product, ColoAlert®, is reported to miss far fewer cases than competing tests – up to 60% fewer, according to Mainz. Building on this success, their next-generation FIT (fecal immunochemical test) incorporates a proprietary algorithm utilizing artificial intelligence and machine learning to identify mRNA biomarkers, potentially offering even better early detection of colorectal cancer.
Mainz Biomed’s approach could represent a new gold standard for noninvasive detection of advanced adenomas. The company is planning an FDA pre-market approval study in 2025 for its next-generation test, with a focus on distributing the test kit through existing networks of FDA-approved national reference testing laboratories in the United States. This strategy differs from current market offerings, where companies typically control both the test kits and the testing process.
The potential impact of Mainz Biomed’s technology extends beyond improving detection rates. Early detection of colorectal cancer is critical for patient outcomes, with early-stage detection associated with a 90% survival rate, compared to just 10% for late-stage detection. By potentially catching more cases early, Mainz’s test could significantly improve survival rates and reduce the overall burden of colorectal cancer on public health.
As Mainz Biomed progresses towards its goals, the company is focusing on strategic partnerships to enhance its market approach. Plans include collaborating with a PCR provider and a national reference lab, which will be crucial for conducting the FDA pre-market approval study and implementing a commercial go-to-market strategy.
The colorectal screening market represents a substantial opportunity, with the U.S. market alone valued at over $30 billion annually, according to Caragol. Globally, this figure doubles, highlighting the significant potential for innovative screening solutions like Mainz Biomed’s.
If successful in meeting its milestones and securing FDA approval, Mainz Biomed could be well-positioned to capture a share of this lucrative market. The company’s technology not only promises to improve colorectal cancer screening but could also pave the way for developing test kits for other gastrointestinal cancers, further expanding its potential impact on cancer diagnostics and patient care.
As the medical community and patients alike seek more effective and less invasive screening options, Mainz Biomed’s innovative approach to colorectal cancer detection represents a promising development in the ongoing battle against this deadly disease. The coming years will be critical as the company works towards FDA approval and potential commercialization of its groundbreaking technology.
This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Mainz Biomed Advances Groundbreaking Colorectal Cancer Screening Test.